Atyr Pharma fell 1.5% in premarket trade as investors awaited Phase 3 EFZO-FIT trial results of efzofitimod in pulmonary sarcoidosis, a potential inflection point. Analysts remain upbeat, with Jefferies, H.C. Wainwright, Cantor, and Leerink all maintaining bullish calls. Retail sentiment on Stocktwits stayed 'bullish' amid high activity. ATYR is up 66.6% in 2025.